STEP-PRESS is a predefined exploratory observational substudy nested within the STEPCARE trial. The study will evaluate whether early low pulse-pressure burden after out-of-hospital cardiac arrest is associated with early mortality and selected biomarker outcomes. Pulse pressure will be calculated as systolic blood pressure minus diastolic blood pressure using recorded STEPCARE blood-pressure values. The primary exposure is cumulative hours with pulse pressure below 40 mmHg during the first 12 hours after randomization. The primary outcome is all-cause mortality from the 12-hour landmark to day 7.
STEP-PRESS is a predefined exploratory observational substudy nested within STEPCARE, an international, multicenter, randomized factorial trial of intensive-care strategies after out-of-hospital cardiac arrest. STEPCARE is registered as NCT05564754. The STEPCARE biomarker substudy is registered as NCT06471972. STEP-PRESS will use data collected within the STEPCARE trial and applicable substudy approvals. No additional intervention, patient contact, or deviation from STEPCARE clinical management is planned for STEP-PRESS. The source population will consist of randomized STEPCARE participants, excluding consent withdrawals. Pulse pressure will be calculated as systolic blood pressure minus diastolic blood pressure using recorded STEPCARE blood-pressure values. The primary exposure is cumulative low pulse-pressure burden, defined as the number of hours during 0 to 12 hours after randomization in which interpolated pulse pressure is below 40 mmHg. The primary analysis population will be restricted to participants alive 12 hours after randomization, without mechanical circulatory support initiated before or within 24 hours after randomization, and with at least three valid recorded blood-pressure observations during 0 to 12 hours after randomization. The primary outcome is all-cause mortality from the 12-hour landmark to day 7. Key secondary outcomes include mortality in a 24-hour landmark analysis, neurological biomarker endpoints, 30-day mortality, 6-month survival, and 6-month functional outcome. Six-month poor functional outcome will follow the parent STEPCARE definition of modified Rankin Scale score 4 to 6. All STEP-PRESS objectives are associational. The substudy is not designed to test whether modifying pulse pressure improves outcomes.
Study Type
OBSERVATIONAL
Enrollment
3,500
Department of Intensive Care, Skåne University Hospital
Malmö, Sweden
All-Cause Mortality From 12 Hours to Day 7
Death from any cause occurring after the 12-hour landmark and through day 7 after randomization, evaluated in relation to cumulative low pulse-pressure burden below 40 mmHg during 0 to 12 hours after randomization.
Time frame: From 12 hours after randomization through day 7 after randomization
All-Cause Mortality in the 24-Hour Landmark Analysis
Death from any cause occurring after the 24-hour landmark and through day 7 after randomization, evaluated in relation to cumulative low pulse-pressure burden below 40 mmHg during 0 to 24 hours after randomization.
Time frame: From 24 hours after randomization through day 7 after randomization
Neurofilament Light Level at 12 Hours
Neurofilament light concentration at 12 hours after randomization, analyzed among participants in the STEPCARE biomarker substudy with available biomarker data.
Time frame: 12 hours after randomization
Neuron-Specific Enolase Level at 48 Hours
Neuron-specific enolase concentration at 48 hours after randomization, analyzed using available STEPCARE measurements.
Time frame: 48 hours after randomization
30-Day All-Cause Mortality
Death from any cause within 30 days after randomization.
Time frame: 30 days after randomization
6-Month Survival
Survival status at 6 months after randomization.
Time frame: 6 months after randomization
Poor Functional Outcome at 6 Months
Poor functional outcome at 6 months after randomization, defined according to the parent STEPCARE definition as modified Rankin Scale score 4 to 6.
Time frame: 6 months after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.